KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) FCF Margin (2020 - 2025)

Historic FCF Margin for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to 2272.52%.

  • Recursion Pharmaceuticals' FCF Margin fell 20279600.0% to 2272.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 1024.72%, marking a year-over-year decrease of 5149500.0%. This contributed to the annual value of 633.71% for FY2024, which is 387200.0% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its FCF Margin stood at 2272.52% for Q3 2025, which was down 20279600.0% from 413.92% recorded in Q2 2025.
  • Recursion Pharmaceuticals' FCF Margin's 5-year high stood at 1369.7% during Q1 2022, with a 5-year trough of 2590.68% in Q4 2021.
  • In the last 5 years, Recursion Pharmaceuticals' FCF Margin had a median value of 699.37% in 2023 and averaged 988.37%.
  • Data for Recursion Pharmaceuticals' FCF Margin shows a peak YoY increase of 288767300bps (in 2021) and a maximum YoY decrease of -27722500bps (in 2021) over the last 5 years.
  • Over the past 5 years, Recursion Pharmaceuticals' FCF Margin (Quarter) stood at 2590.68% in 2021, then soared by 85bps to 385.54% in 2022, then plummeted by -81bps to 699.15% in 2023, then plummeted by -267bps to 2567.71% in 2024, then increased by 11bps to 2272.52% in 2025.
  • Its FCF Margin was 2272.52% in Q3 2025, compared to 413.92% in Q2 2025 and 907.35% in Q1 2025.